FDA Approves Expanded Indication for Anktiva in BCG-Unresponsive NMIBC
PharmaMar Joins OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition as Foundational Partner
Jazz EMERGE 402: Real-World Lurbinectedin Shows Clinically Meaningful Activity in Previously Treated SCLC
Men and Breast Cancer: More than just a support system
FFCD-AC: 1L Chemotherapy for Metastatic Recurrence of Ampullary Adenocarcinoma
Giuseppe Curigliano Announces Milan as Host City for ESMO Congress 2028
The Advocacy Lens - Breast Cancer Awareness Month Special
Ulrika Årehed Kågström: The Hidden Financial Burden of Cancer Beyond Treatment
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
